Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation

Germain, 2020, Delivering the power of nanomedicine to patients today, J. Control. Release, 326, 164, 10.1016/j.jconrel.2020.07.007 Noorlander, 2015, Horizon scan of nanomedicinal products, Nanomedicine (London), 10, 1, 10.2217/nnm.15.21 Dimitriou, 2017, Gold nanoparticles, radiations and the immune system: current insights into the physical mechanisms and the biological interactions of this new alliance towards cancer therapy, Pharmacol. Ther., 178, 1, 10.1016/j.pharmthera.2017.03.006 Geertsma, 2015, Nanotechnologies in medical devices, RIVM Rep., 0149 Halamoda-Kenzaoui, 2020, Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products, Precis. Nanomedicine, 3, 608, 10.33218/001c.13521 FDA, 2017, Drug Products, Including Biological Products, that Contain Nanomaterials EMA/CHMP, 2013 FDA MHLW EMA/CHMP, 2013 EMA/CHMP, 2015 MHLW SCENIHR, 2015, Opinion on the guidance on the determination of potential health effects of nanomaterials used in medical devices, Final Opin., 1 ISO/TC 194, 2012 Halamoda-Kenzaoui, 2019, Anticipation of regulatory needs for nanotechnology-enabled health products- The REFINE White Paper, Publ. Off. Eur. Union. EUR, 29919 EMA, 1995, 2 EMA/CHMP, 2011 EMA/CHMP, 2016 Halamoda-Kenzaoui, 2019, Mapping of the available standards against the regulatory needs for nanomedicines, Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology., 11, 10.1002/wnan.1531 Giannakou, 2020, Nonclinical regulatory immunotoxicity testing of nanomedicinal products : proposed strategy and possible pitfalls, WIREs Nanomed Nanobiotechnol., 12, 10.1002/wnan.1633 Crist, 2013, Common pitfalls in nanotechnology: lessons learned from NCI’s nanotechnology characterization laboratory, Integr. Biol., 5, 66, 10.1039/c2ib20117h SCENIHR EMA/CHMP, 2013 Varache, 2019, Development and validation of a novel UPLC-ELSD method for the assessment of lipid composition of nanomedicine formulation, Int. J. Pharm., 566, 11, 10.1016/j.ijpharm.2019.05.038 Rabanel, 2019, Nanoparticle heterogeneity: an emerging structural parameter influencing particle fate in biological media?, Nanoscale., 11, 383, 10.1039/C8NR04916E Gao, 2018, Progress towards standardized and validated characterizations for measuring physicochemical properties of manufactured nanomaterials relevant to nano health and safety risks, NanoImpact., 9, 14, 10.1016/j.impact.2017.09.002 Praetorius, 2014, The road to nowhere: equilibrium partition coefficients for nanoparticles, Environ. Sci. Nano., 1, 317, 10.1039/C4EN00043A Valsesia, 2018, Direct quantification of nanoparticle surface hydrophobicity, Commun. Chem., 1, 1, 10.1038/s42004-018-0054-7 NanoReg, 2016, 1 Fairhurst, 2016, Relaxation NMR as a tool to study the dispersion and formulation behavior of nanostructured carbon materials, Magn. Reson. Chem., 54, 521, 10.1002/mrc.4218 Cristina, 2019, Strych, establishing preferred product characterization for the evaluation of rna vaccine antigens, Vaccines, 7 Guillot, 2015, Solid phase extraction as an innovative separation method for measuring free and entrapped drug in lipid nanoparticles, Pharm. Res., 32, 3999, 10.1007/s11095-015-1761-8 Skoczen, 2015, Stable isotope method to measure drug release from nanomedicines, J. Control. Release, 220, 169, 10.1016/j.jconrel.2015.10.042 Hu, 2020, The utility of asymmetric flow field-flow fractionation for preclinical characterization of nanomedicines, Anal. Bioanal. Chem., 412, 425, 10.1007/s00216-019-02252-9 Berrecoso, 2020, Unveiling the pitfalls of the protein corona of polymeric drug nanocarriers, Drug Deliv. Transl. Res., 10, 730, 10.1007/s13346-020-00745-0 Monopoli, 2013, Formation and characterization of the nanoparticle-protein corona, Methods Mol. Biol., 1025, 137, 10.1007/978-1-62703-462-3_11 Krause, 2019, Chemical and physical instabilities in manufacturing and storage of therapeutic proteins, Curr. Opin. Biotechnol., 60, 159, 10.1016/j.copbio.2019.01.014 Ivask, 2018, Methodologies and approaches for the analysis of cell-nanoparticle interactions, Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology., 10, 10.1002/wnan.1486 Montaño, 2016, Single particle ICP-MS: advances toward routine analysis of nanomaterials, Anal. Bioanal. Chem., 408, 5053, 10.1007/s00216-016-9676-8 Wong, 2020, Cellular assays and applied technologies for characterisation of orally administered protein nanoparticles: a systematic review, J. Drug Target., 28, 585, 10.1080/1061186X.2020.1726356 Semete, 2010, In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles, Toxicol. Appl. Pharmacol., 249, 10.1016/j.taap.2010.09.002 Boraschi, 2017, Nanoparticles and innate immunity: new perspectives on host defence, Semin. Immunol., 34, 33, 10.1016/j.smim.2017.08.013 Halamoda-Kenzaoui, 2018, Main trends of immune effects triggered by nanomedicines in preclinical studies, Int. J. Nanomedicine, 13, 5419, 10.2147/IJN.S168808 ICH, Immunotoxicity Studies For Human Pharmaceuticals S8 ISO/TC 194, 2006, 26, 54 R. Guadagnini, B. Halamoda Kenzaoui, L. Cartwright, G. Pojana, Z. Magdolenova, D. Bilanicova, M. Saunders, L. Juillerat, A. Marcomini, A. Huk, M. Dusinska, L.M. Fjellsbø, F. Marano, S. Boland, Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests., Nanotoxicology. 9 (2015) 13–24. http://www.ncbi.nlm.nih.gov/pubmed/23889211. Dobrovolskaia, 2014, Choice of method for endotoxin detection depends on nanoformulation, Nanomedicine (London), 9, 1847, 10.2217/nnm.13.157 Giannakou, 2016, Immunotoxicity testing of nanomedicinal products: possible pitfalls in endotoxin determination, Curr. Bionanotechnol., 2, 95, 10.2174/2213529402666160601115600 Smulders, 2012, Contamination of nanoparticles by endotoxin: Evaluation of different test methods, Part. Fibre Toxicol., 9, 10.1186/1743-8977-9-41 Giannakou, 2019, Sensitive method for endotoxin determination in nanomedicinal product samples, Nanomedicine., 14, 1231, 10.2217/nnm-2018-0339 Lu, 2009, Efficacy of simple short-term in vitro assays for predicting the potential of metal oxide nanoparticles to cause pulmonary inflammation, Environ. Health Perspect., 117, 241, 10.1289/ehp.11811 Braune, 2019, In vitro thrombogenicity testing of biomaterials, Adv. Healthc. Mater., 8, 10.1002/adhm.201900527 Guildford, 2009, Nanoparticles of a different source induce different patterns of activation in key biochemical and cellular components of the host response, J. R. Soc. Interface, 6, 1213, 10.1098/rsif.2009.0021 Szebeni, 2012, Liposome-induced complement activation and related cardiopulmonary distress in pigs: Factors promoting reactogenicity of Doxil and AmBisome, Nanomed. Nanotechnol. Biol. Med., 8, 10.1016/j.nano.2011.06.003 Szebeni, 2014, Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals, Mol. Immunol., 61, 163, 10.1016/j.molimm.2014.06.038 Cunningham, 1979, Activation of human complement by liposomes: A model for membrane activation of the alternative pathway, J. Immunol., 122, 10.4049/jimmunol.122.4.1237 Salvador-Morales, 2009, Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups, Biomaterials., 30, 2231, 10.1016/j.biomaterials.2009.01.005 Wang, 2016, Activation of human complement system by dextran-coated iron oxide nanoparticles is not affected by dextran/Fe ratio, hydroxyl modifications, and crosslinking, Front. Immunol., 7, 10.3389/fimmu.2016.00418 Benasutti, 2017, Variability of complement response toward preclinical and clinical Nanocarriers in the general population, Bioconjug. Chem., 28, 2747, 10.1021/acs.bioconjchem.7b00496 Vu, 2019, Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles, Nat. Nanotechnol., 14, 260, 10.1038/s41565-018-0344-3 Chen, 2017, Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo, Nat. Nanotechnol., 12, 387, 10.1038/nnano.2016.269 Sun, 2013, NLRP3 inflammasome activation induced by engineered nanomaterials, Small., 9, 1595, 10.1002/smll.201201962 Lonez, 2014, Cationic lipid nanocarriers activate toll-like receptor 2 and NLRP3 inflammasome pathways, Nanomed. Nanotechnol. Biol. Med., 10, 775, 10.1016/j.nano.2013.12.003 Li, 2017, Targeting TNFα ameliorated cationic PAMAM Dendrimer-induced hepatotoxicity via regulating NLRP3 Inflammasomes pathway, ACS Biomater. Sci. Eng., 3, 843, 10.1021/acsbiomaterials.6b00790 Sussman, 2014, Porous implants modulate healing and induce shifts in local macrophage polarization in the foreign body reaction, Ann. Biomed. Eng., 42, 1508, 10.1007/s10439-013-0933-0 Kagan, 2002, A role for oxidative stress in apoptosis: oxidation and externalization of Phosphatidylserine is required for macrophage clearance of cells undergoing Fas-mediated apoptosis, J. Immunol., 169, 487, 10.4049/jimmunol.169.1.487 NANOMMUNE, 2011 Potter, 2018, Methods for analysis of nanoparticle immunosuppressive properties In vitro and in vivo, 161, 10.1007/978-1-4939-7352-1_14 Galbiati, 2010, Present and future of in vitro immunotoxicology in drug development, J. Immunotoxicol., 7, 255, 10.3109/1547691X.2010.509848 Germolec, 2017, Immunotoxicology: a brief history, current status and strategies for future immunotoxicity assessment, Curr. Opin. Toxicol., 5, 55, 10.1016/j.cotox.2017.08.002 Brodin, 2017, Human immune system variation, Nat. Rev. Immunol., 17, 21, 10.1038/nri.2016.125 Dobrovolskaia, 2013, Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines, J. Control. Release, 172, 456, 10.1016/j.jconrel.2013.05.025 Ali, 2010, Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a, Immunol. Lett., 128, 36, 10.1016/j.imlet.2009.10.007 Soruri, 2003, IL-4 Down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo, J. Immunol., 170, 3306, 10.4049/jimmunol.170.6.3306 Takabayashi, 2004, Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells, Surgery., 135, 544, 10.1016/j.surg.2003.09.010 GSRS, Nanotechnology Standards and Applications. Report, (2016) 1–35. https://www.astm.org/COMMIT/GSRS16 Final Report.pdf.